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Summary. The pathophysiology of various stages of hyper- 
tension is different. In early hyperkinetic borderline hyper- 
tension, the sympathetic drive to the heart and blood vessels 
is increased while the parasympathetic cardiac inhibition is 
decreased. The elevated cardiac output, vascular resistance, 
and blood pressure at that stage can be fully normalized by 
autonomic blockade. As hypertension advances, a hyperki- 
netic circulation is less evident, since beta-adrenergic respon- 
siveness and cardiac compliance tend to decrease. Simulta- 
neously hypertrophy of the resistance vessels increases the 
baseline vascular resistance and the vessels' responsiveness 
to constrictive stimuli. Eventually a picture of a normal car- 
diac output/high vascular resistance typical for established 
essential hypertension emerges. As the blood vessels become 
hyperreactive, the same degree of vasoconstriction/blood 
pressure elevation can be achieved with less sympathetic 
tone. In that phase the sympathetic overactivity is less evi- 
dent, as the brain resets itself to maintain the same blood 
pressure elevation with a small amount of sympathetic dis- 
charge. While sympathetic overactivity may be less evident 
in established hypertension, it remains an important patho- 
physiologic factor, not only for the maintenance of blood 
pressure, but also for a number of other abnormalities in 
hypertension. Hypertension is intimately associated with 
higher levels of pressure.unrelated risk for development of 
atherosclerosis: dyslipidemia, overweight, and hyperinsu- 
linemia. Furthermore, a number of factors in hypertension 
favor a poorer outcome from coronary heart disease. These 
pressure-independent factors increase the risk of coronary 
thrombosis, arrhythmie deaths, and coronary spasms. Sym- 
pathetic overreactivity appears to be crucially implicated in 
the evolution of this added coronary risk in hypertension. 
Understanding the pathophysiology of coronary risk and its 
relationship to sympathetic overreactivity in hypertension is 
helpful in seeking further improvements in clinical practice. 
At present antihypertensive treatment is less efficacious in 
reducing coronary events in hypertension than would be ex- 
pected. Judicious use of appropriate drugs promises to fur- 
ther improve the efficacy of antihyportensive treatment in 
those patients who, in addition to high blood pressure, also 
have other associated risk factors. 
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tigators started to focus on the possible role of sympa- 
thetic overactivity as a mechanism for elevated blood 
pressure. In 1905, Geisbock [1] described among his 
patients with polycythemic hypertension an "unusual 
frequency of directors of big enterprises who had de- 
manding jobs and who, due to psychic overwork, be- 
came nervous." In 1933, in one of the earlier reports 
on hypertension in the United States, Ayman [2] de- 
scribed the passive-submissive personality of his pa- 
tients. However in the 1960s and 1970s, the interest 
in the role of the nervous system in hypertension sub- 
stantially declined. A few factors contributed to this 
state of affairs. First was that arterial baroreceptors 
are reset to maintain higher blood pressure after the 
development of experimental hypertension [3] and 
that removal of baroreceptor inhibition does not result 
in permanent hypertension [4,5]. The second impor- 
tant factor in the non-neurogenic orientation of the 
hypertension research reflects animal modeling of hy- 
pertension. Research is the art of the feasible, and 
phenomena that are hard to measure or difficult to 
model receive less attention. The ease of generating 
hypertension in animals with stenosis of the renal ar- 
tery, partial ablation of the kidney, DOCA/salt, and 
other interventions influenced the direction of re- 
search. In contrast, it still is very difficult to generate 
experimentally a neurogenic hypertension. Barore- 
ceptor debuffering failed mainly because the barore- 
ceptors seem to regulate blood pressure variability 
but not the setting of the average blood pressure 
level. Repeated stressors such as noise [6], electrical 
stimulation of the paleocortex [7], or shock/avoidance 
in dogs [8] failed to induce long-lasting and self- 
perpetuating hypertension. 
The third reason for doubts about the role of the 
nervous system in hypertension stems from human 
research: Plasma catecholamines are elevated in 
young subjects with mild hypertension but not in 
more advanced forms of hypertension [9,10]. 
The failure to create an animal model of neurogenic 
hypertension is somewhat fortuitous, as it forced in- 
In  the beginning of this century, as soon as clinical 
blood pressure measurement became available, inves- 
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vestigators to concentrate on human investigations. I 
strongly believe that animal modelling, while ex- 
plaining how various organs suffer in response to high 
blood pressure, has little to offer for understanding 
the etiology of human hypertension. How do the in- 
bred animal models resemble human hypertension and 
which model applies to which subset of patients with 
hypertension? Since animal experimentation up to to- 
day have failed to elucidate the nature of human hy- 
pertension, and the methods of clinical investigation 
grew more sophisticated, the pendulum has switched 
towards an increasing interest in the role of the ner- 
vous system in human hypertension. Furthermore, 
awareness is increasing that the nervous system is 
intimately involved in the pathophysiology of diverse 
forms of experimental hypertension. Destruction of 
the AV3V region in the midbrain prevents the occur- 
rence of renovascular, DOCA, and other sodium- 
sensitive forms of hypertension [11]. Studies of the 
Okamoto spontaneously hypertensive rat, a strain 
claimed to be "most similar to human hypertension," 
also shows a strong neurogenic component in its 
pathophysiology [12,13]. 
In this review I will show that the role of autonomic 
abnormality in human hypertension is well under- 
stood; that we now can explicate the transition from 
early phases of hypertension, which clearly is neuro- 
genic, to later phases, which appear to be less neuro- 
genic; and that understanding the pathophysiologic 
role of the nervous system may explain many clinically 
important aspects of hypertension. 
The Changing Face of Autonomic 
Abnormality in Hypertension 
Young patients with borderline hypertension fre- 
quently show a hyperkinetic state of increased cardiac 
output and a faster heart rate [14-20]. The increase 
of heart rate and cardiac output in these individuals 
is neurogenic and can be abolished with receptor- 
blocking agents [21]. Interestingly, the hyperkinetic 
state is due both to more beta-adrenergic drive and 
less parasympathetic inhibition of the heart. This, in 
turn, suggests that abnormality is of central nervous 
origin and emanates from the medulla oblongata, 
where sympathetic and parasympathetic tone are in- 
tegrated in a reciprocal fashion. Plasma norepineph- 
rine levels in hyperkinet.ic borderline hypertension 
are elevated [22]. Blood pressure elevation, per se, is 
also neurogenic; a complete autonomic blockade, in- 
cluding alpha-adrenoreceptor blockade, normalizes 
the blood pressure in these patients [23]. Recently 
direct microneurography documented a consistent ele- 
vation of the number of sympathetic impulses in the 
peroneal nerve of patients with borderline hyperten- 
sion [24]. 
These lines of evidence strongly support the im- 
portance of the autonomic nervous abnormalities in 
borderline hypertension. Nevertheless, these obser- 
vations leave a number of open questions. First is 
whether patients studied in laboratories are represen- 
tative of the average population of patients with hy- 
pertension. For example, it is possible that health- 
conscious, concerned, and a priori anxious patients are 
over-represented among volunteers for studies in 
highly specialized, hospital-based laboratories. Patho- 
physiologic abnormalities in them may be an acute 
reaction to the procedure of measurement unrelated 
to the mechanism of hypertension. However, this is 
not the case. In the field study in Tecumseh we uti- 
lized noninvasive and nonthreatening methods to as- 
sess hemodynamics in unselected subjects, many of 
whom were unaware of having a blood pressure 
"problem." Nevertheless the findings were similar as 
in the hospital laboratory; in excess of 30% of all sub- 
jects with borderline hypertension had a hyperkinetic 
circulation, their plasma norepinephrine levels were 
elevated, they came from families with higher blood 
pressure, and these individuals, who during the re- 
cent exam on average were 32 years of age, showed 
significant blood pressure elevation already as chil- 
dren at 7 years of age [22]. These findings suggest 
that a neurogenic borderline hypertensive is fre- 
quently seen in the general population and that the 
condition starts very early in life. 
A second set of questions pertains to the natural 
history of neurogenic borderline hypertension. Do pa- 
tients with hyperkinetic borderline hypertension later 
develop sustained hypertension? If the answer is yes ,  
why do we find elevated resistance and a normal car- 
diac output in established hypertension? If they start 
with a high cardiac output and end up with elevated 
vascular resistance, what is the mechanism of this he- 
modynamic transition? 
The first of these questions can be answered with 
relative ease. A number of epidemiologic studies docu- 
ment tachycardia, the hallmark of the hyperkinetic 
state, to be predictive of future hypertension [25-27]. 
Furthermore, as the blood pressure increases from 
borderline to established higher values, cohort studies 
have documented the transition from a high output to 
a high resistance state. Initial short studies (up to 5 
years), while confirming the hemodynamic transition, 
were unable to convincingly show the development 
of established hypertension in these patients. More 
recently, Dr. Lund Johansen reported on 20 years of 
follow-up in his subjects with hyperkinetic borderline 
hypertension [28]. In this unique study, after 20 years 
almost all subjects developed a treatment-requiring, 
high-resistance type of hypertension. 
We believe that the transition from the high cardiac 
output to a high resistance reflects a decrease of car- 
diac and an increase of vascular responsiveness in 
the course of hypertension. Two elements affect the 
decreased cardiac responsiveness: prolonged sym- 
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pathetic stimulation leads to a decrease of beta- 
adrenergic responsiveness and the elevated blood 
pressure causes an early decrease of cardiac compli- 
ance, which, in turn, decreases stroke volume [29]. 
Simultaneously with this decrease of heart rate and 
stroke volume, the longstanding blood pressure ele- 
vation tends to accentuate the vasoconstriction in re- 
sistance vessels. Many years ago Dr. Bjorn Folkow 
first proposed the principle and later experimentally 
demonstrated that the geometry of a vessel's wall af- 
fects the resistance responsiveness of that vessel [30]. 
Blood pressure elevation leads to vascular hypertro- 
phy and a thickening of the medial (muscular) layer 
in the vessel's wail. As the blood vessel constricts, the 
thicker wall encroaches more on the lumen. Vascu- 
lar resistance is a fourth power function of the radius 
and vasoconstriction in patients with hypertrophic 
blood vessels causes a larger increase of vascular re- 
sistance than in normal subjects. This enhancement of 
vasoconstriction is nonspecific and the blood vessels 
are hyper-responsive to all vasoconstrictive stimuli. 
Such early changes in vascular structure have been 
documented in hypertension [31,32]. There is some 
discussion as to whether, in addition to these nonspe- 
cific changes hypertensive patients also show specific 
aipha-adrenergic hyper-responsiveness [33-35]. 
All these changes contribute to an alteration of the 
hypertensive phenotype. The telltale signs of neuro- 
genic involvement in early hypertension - -  the fast 
heart rate and increased cardiac output - -  are not 
evident in established hypertension. What looked as 
clearly neurogenic disease in the beginning later ap- 
pears unrelated to sympathetic overactivity. How- 
ever, in addition to these changes in the peripheral 
responsiveness in the course of hypertension, the ac- 
tual sympathetic tonic discharge from the central ner- 
vous system appears also to decrease slowly. Plasma 
norepinephrine values are elevated in young patients 
with hyperkinetic hypertension [2-2] but such an eleva- 
tion cannot be documented in older subjects with es- 
tablished hypertension [9,10]. As hypertension ad- 
vances, a similar downward trend in sympathetic 
activity has also been observed in studies utilizing 
norepinephrine "spillover" rates to assess the sympa- 
thetic tone [36]. What could be the mechanism of this 
resetting of sympathetic tone? In the absence of a 
direct answer, we recently proposed a hypothesis that 
provides the conceptual framework to explain this 
transition [37]. 
The hypothesis is based on numerous observations 
about the "blood pressure seeking property of the cen- 
tral nervous system." In order to tightly regulate cir- 
culation, the autonomic control of circulation functions 
as a negative feedback system (Figure 1). Whenever 
there is a perturbance in circulation, the feedback 
trends to determine the magnitude of the response 
in order to assure a new equilibrium. As Figure 1 
illustrates, in circulation the feedback from the pe- 
® 
Pressure : Flow x Resistance 
® 
Fig. 1. The general scheme of the negative feedback from the 
circulation to the central nervous system (CNS). Adapted 
from data in Julius et al. [37] with permission. 
riphery to the brain must be related to one of the 
primary circulatory variables: pressure, flow, or resis- 
tance. In terms of feedback loops, the variable that is 
most tightly controlled is the regulated variable. Dr. 
Guyton correctly points out that the long-term pur- 
pose of circulation must be to regulate the flow [38]. 
In his volume-dependent models, when the minute 
volume (cardiac output) is perturbed, pressure and 
resistance adjusts to secure an optimal flow (autoregu- 
lation). Under those circumstances the flow is the reg- 
ulated variable. 
However, we maintain the central nervous sys tem 
subserves the circulation by regulating blood pres- 
sure. It will be shown that under a number of circum- 
stances the central nervous system permits wide vari- 
ations of resistance and flow but very closely regulates 
the pressor response. To follow this argument the 
reader should become familiar with the graphic pre- 
sentation of the basic relationship between flow, pres- 
sure, and resistance given in Figure 2. The degree to 
which the flow increases in response to an elevation 
of the pressure depends on resistance to flow. Resis- 
tance, in turn, is largely dependent on the cross- 
sectional area of all vascular lumina in the circulation. 
When the blood vessels are widely open (Figure 2, 
isoresistance, line 1) resistance is low and a small in- 
crease of pressure elicits a large increase of flow. 
When the blood vessels are constricted and resistance 
is high, a large increase of pressure results in only a 
small increase of flow (Figure 2, isoresistance, line 5). 
This diagram permits simultaneous assessment of the 
relationship between the three principal components 
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F~g. 2. The pressure-flow-resistance relationship. The diago- 
nal lines are lines of isoresistance. The lowest diagonal lines 
represent low resistance, and the highest lines represent high 
resistance. Note that the vascular caliber at low resistance is 
larger and that small increases in pressure cause a large in- 
crease inflow. At  the high resistance line the vascular caliber 
is narrow and a large increase in pressure causes only a 
small increase in flow. The horizontal vector represents a de- 
crease in flow, associated with an increase in resistance and 
no change in pressure. The diagonal, downwardly pointing 
vector represents a decrease inflow with an unchanged resis- 
tance and a faU in blood pressure. Adapted from data in 
Julius et al. [37]. 
of circulation. Pressure and flow can be read from the 
corresponding axis, whereas the direction of the 
arrow in relationsip to the isoresistance lines denotes 
a change in resistance. 
Examples of how the central nervous system pre- 
serves the blood pressure response are shown in Fig- 
ures 3 and 4. The point of both illustrations is that 
under proper experimental circumstances one can 
prevent the usual hemodynamic response but this will 
not  af fect  the m a g n i t u d e  o f  the blood pres sure  re- 
sponse.  For example, in Figure 3 the usual response 
to isometric exercise, which is a rise in cardiac output, 
did not occur in patients with poor myocardial func- 
tion, but blood pressure response was preserved. In- 
stead of an increase of cardiac output, the poor cardiac 
function group responded with an increase of vascular 
resistance [39]. An example in the opposite direction 
is given in Figure 4. The usual hemodynamic response 
to hindquarter compression in dogs is resistance- 
mediated neurogenic increase of blood pressure [40]. 
When the increase of resistance is prevented with 
alpha-adrenergic blockade, the blood pressure re- 
sponse is preserved through an increase of cardiac 
Fig. 3. Response to isometric exercise in patients recovering 
from myocardial infarction. Six subjects had a normal car- 
diac output response ( ........ *). Eight patients had poor cardiac 
function and failed to increase output ( O. MBP = 
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Fig 4. Response to 60 minutes of hindquarter compression in 
eight chloralose-anesthetized dogs. - ........ , response before phen- 
oxybenzamine; ) response to 60 minutes of compression 
after 1 mg/kg phenoxybenzamine (i.v.). MBP = mean blood 
pressure. Adapted from data in Julius et al. [41]. 
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output [41]. This principle that blood pressure re- 
sponse is obligatory and stereotypical but the underly- 
ing hemodynamics can be either cardiac or vascular, 
depending on which system is rendered unresponsive, 
has also been documented for mental arithmetic [42], 
isometric exercise [43], stellate ganglion stimulation 
[44], and response to noise [45]. 
Preservation of blood pressure response in the ex- 
periments cited above implies that feedback informa- 
tion to the central nervous system is pressure related 
and independent of the state of the resistance or flow. 
To be able to stabilize response at the desired blood 
pressure level, the brain must be capable of sensing 
the achieved blood pressure. It follows that the direc- 
tion (to vessels or the heart) and the magnitude of 
the central nervous discharge largely depends on re- 
sponsiveness of the peripheral organs. Within the con- 
text of this blood pressure seeking property of the 
central nervous system, the observed sequence of 
events in borderline and advanced hypertension is to 
be expected. If the brain in hypertension seeks to 
maintain a higher average blood pressure level as vas- 
cular responsiveness increases with the progression 
of hypertension, the brain can achieve the same blood 
pressure level with less sympathetic firing. The pri- 
mary mechanism of hypertension may still be neuro- 
genic, but due to increased vascular responsiveness 
the absolute sympathetic tone will not be increased. 
In summary, there is good evidence for a strong 
neurogenic component in early phases of hyperten- 
sion, particularly in so-called hyperkinetic borderline 
hypertension (high cardiac output and a fast heart 
rate). This condition may be present in about 30% of 
patients with borderline hypertension, and it has 
been shown that these patients 6ventually do develop 
established treatment-requiring hypertension. As 
hypertension escalates the hemodynamic pattern 
changes from a high cardiac output to a high resis- 
tance pattern. The transition from high cardiac output 
to high resistance is best explained by alteration in the 
structure and responsiveness of the heart and blood 
vessels. Decreased cardiac compliance and diminished 
beta-adrenergic responsiveness tend to decrease car- 
diac output, whereas the development of vascular hy- 
pertrophy increases vascular resistance. In parallel 
the sympathetic tone appears to be down-regulated, 
since with emerging vascular hyperresponsiveness 
less sympathetic drive is needed to maintain the vaso- 
constriction-related hypertension. 
Sympathetic Overactivity 
and Multiple Coronary Risk 
in Hypertension 
Blood pressure elevation is only part of a larger prob- 
lem in patients with borderline hypertension. Behind 
the facade of mild blood pressure elevation hides a 
number of other pathophysiologie abnormalities. Of 
particular interest is the coaggregation of coronary 
risk factors with blood pressure elevation in border- 
line and established hypertension. These can be bro- 
ken down into proatherogenic factors and factors that 
increase the risk of complications in patients who have 
already developed coronary heart disease. We will 
show that the autonomic nervous system plays an im- 
portant role in the development of these risk factors. 
Acceleration of atherosclerosis 
Table 1 shows atherosclerotic risk factors in patients 
with borderline hypertension in Tecumseh. It should 
be pointed out that blood pressure elevation in these 
patients is minimal; their clinical reading was 130/94 
mmHg, but when they measured their own blood 
pressure at home the average reading was 126/80 
mmHg [46]. Furthermore, when patients with "white 
coat hypertension" (normal blood pressure at home) 
were compared to the "sustained" hypertension sub- 
group (high blood pressure both in the clinic and at 
home), subjects with only transient hypertension had 
significantly higher levels of coronary risk than the 
normotensive population [47]. 
The coaggregation of coronary risk with hyperten- 
sion is astonishing. From the very beginning of the 
disease in its mildest possible form, patients are not 
only burdened with a higher blood pressure level but 
are also overweight, their HDL cholesterol is de- 
creased, and their cholesterol, triglyceride, and insu- 
lin levels are elevated. All of these are known risk 
factors for coronary heart disease. Obviously the 
higher coronary risk in hypertension does not reflect 
only the blood pressure elevation but also these other 
associated risk factors. Why should all these abnor- 
malities be found in the same persons? I will marshal 
evidence to suggest that the increased sympathetic 
tone, which maintains the higher blood pressure, is 
also responsible for the elevation of plasma insulin lev- 
els in borderline hypertension. Through its "trophic" 
effect on smooth muscle cell growth [48-50], high in- 
sulin is an independent risk factor for atherosclerosis 
[51-53]. Furthermore, high insulin levels in insulin- 
resistant states may contribute to dyslipidemias [54]. 
High insulin is a sign of insulin resistance in hyper- 
tension, and the skeletal muscles are the major site 
of the tissue resistance to insulin [55,56]. Enhanced 
sympathetic drive may be conducive to insulin resis- 
tance through a number of mechanisms. First, it 
is known that beta-adrenergic stimulation causes a 
receptor-mediated insulin resistance [57]. Second, 
chronic beta-adrenergic stimulation causes an in- 
crease in the number of fast-twitch insulin resistant 
fibers [58]. 
Alpha-adrenergic vasoconstriction is the third 
mechanism by which sympathetic overactivity could 
lead to insulin resistance. We first proposed the con- 
cept [59] and later provided experimental evidence 
[60] for the notion that vasoconstriction may decrease 
the glucose delivery to the skeletal muscle and 
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Table 1. Indices of body size and risk factors in the two groups a 
Normotensive subjects 
Index (sample size) 
Borderline 
hypertensive subjects 
(sample size) pb 
Weight, kg 74.3 ... 0.5 (801) 87.7 -+ 1.3 (123) <.0001 
Height, cm 170.2 --- 0.2 (801) 170.0 _+ 0.6 (123) NS 
Overweight, % 13.6 ± 0.7 (799) 30.1 _+ 1.9 (123) <.0001 
Triceps skin folds, mm 18.3 ... 0.3 (756) 20.8 -+ 0.8 (112) <.005 
Biceps skin folds, mm 10.4 _ 0.2 (756) 12.6 _+ 0.6 (112) <.031 
Subseapular skin folds, mm 20.6 --- 0.4 (756) 24.1 _ 0.9 (112) <.0005 
Suprascapular skin folds, mm 23.0 _ 0.4 (754) 27.6 - 1.1 (112) <.0001 
Cholesterol, mM/1 4.54 -+ 0.03 (684) 4.92 __ 0.09 (102) <.0001 
High-density lipoprotein, mM/1 1.12 -+ 0.01 (684) 1.04 _+ 0.03 (102) <.001 
Triglycerides, mM/1 1.07 - 0.03 (598) 1.52 _+ 0.08 (86) <.0001 
Insulin, pM/1 88 + 3 (581) 126 - 11 (81) <.0301 
Glucose, mM/L 5.1 -- 0.02 (563) 5.3 - 0.06 (80) <.001 
Insulin/glucose ratio 0.155 ___ 0.004 (485) 0.200 ___ 0.011 (67) <.0031 
Waist/hip ratio 0.83 _ 0.01 (156) 0.86 +- 0.01 (25) <.005 
aValues are mean ± SEM. 
bAnalysis of covariance. NS indicates not significant. 
Adapted from data in Julius et al. [46]. 
thereby cause a relative resistance to the effects of 
insulin. Figure 5 shows the effect of reflex vasocon- 
striction of glucose utilization in the human forearm 
[60]. In this experiment we infused insulin into the 
brachial ar tery  and measured the insulin-induced glu- 
cose utilization in the forearm. Reflex vasoconstriction 
in the forearm was induced by inflating blood pressure 
cuffs on subjects' thighs, thereby decreasing the right 
atrial pressure, which, in turn, triggers increased 
sympathetic tone via cardiopulmonary mechanorecep- 
tors. As the figure shows, reflex vasoconstriction 
caused a decrease of insulin-stimulated glucose uptake 
in the forearm. 
Our experiments are acute and the question arises 
as to whether the results are applicable to chronic 
hypertension. We think that chronic sympathetic 
overstimulation and longstanding blood pressure ele- 
vation in hypertension lead to vascular rarefaction, 
which then may become the mechanism for chronic 
insulin resistance in hypertension. A decrease of capil- 
lary density in various organs, including the skeletal 
muscles, in hypertension has been documented [61- 
64]. 
Enhanced risk of coronary morbidity 
Coronary thrombosis .  Two  factors may favor coro- 
nary thrombosis in hypertension and both of them 
likely reflect increased sympathetic tone. First  is high 
hematocrit, which is often found in hypertension [65]. 
A high hematocrit is an independent predictor of coro- 
nary mortality, most likely through an increase of 
blood viscosity, which increases the chances of coro- 
nary thrombosis [66,67]. Patients with hypertension 
have significantly decreased plasma volume [68], and 
the higher hematocrit values reflect this contraction of 
the intravascular volume. Infusion of norepinephrine 
causes an acute decrease of plasma volume [69], and 
beta-adrenergic blockade with propranolol causes a 
similar decrease of plasma volume [70]. The most 
likely mechanism for the fall in plasma volume after 
these pharmacologic interventions is an alpha- 
adrenergically mediated increase in postcapillary ve- 
nous resistance, leading to an increase in the capillary 
pressure. It  stands to reason that sympathetic vaso- 
constriction may contribute to decreased plasma vol- 
ume and an increase of hematocrit in hypertension. 
The second mechanism conducive to coronary 
thrombosis in hypertension is increased platelet activ- 
ity. Plasma thromboglobulin, a measure of platelet 
turnover, is elevated in hypertension and the eleva- 
tion correlates to increased plasma adrenaline levels 
in these patients [71]. 
Tendency to sudden death. Left ventricular hyper- 
trophy is a major risk factor for arrhythmias and sud- 
den death [72]. At this point the reader  should be 
reminded of the evidence presented earlier in this pa- 
per, of an increased sympathetic and decreased para- 
sympathetic cardiac tone in hypertension. Initially, as 
hypertension advances, cardiac sympathetic tone ap- 
pears to decrease, but later when cardiac performance 
decreases, the heart  again becomes more dependent 
on enhanced sympathetic drive. The decreased para- 
sympathetic tone is a constant feature both in border- 
line [21] and the later established phase of hyperten- 
sion [73]. There is good experimental evidence that 
increased sympathetic tone and decreased parasym- 
pathetic activity are arrhythmogenic [74,75]. It  there- 
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Fig. 5. Line graph shows effect of insulin infusion and reflex sympathetic activation on glucose and oxygen utilization in the fore- 
arm of 1~ healthy volunteers. Reflez activation was elicited by inflation of blood pressure cuffs placed around subjects' thighs. In- 
flation of the cuff to $0 mmHg decreases the venous return and thereby decreases the stretch of cardiopulmonary receptor, which, 
in turn, elicits sympathetic vasoconstriction in the forearm. *Change from insulin to insulin plus thigh cuff, p < 0.03. AVE = av- 
erage; Glc = glucose. Adapted from data in Jamerson et al. [60]. 
fore stands to reason that increased sympathetic and 
decreased parasympathetic tone in hypertension are 
conducive to arrhythmias. 
Increased ventricular size by itself favors arrhyth- 
mias. Again, sympathetic activity may independently 
contribute to this additional risk factor for arrhyth- 
mias. Sympathetic stimulation is recognized as a "tro- 
phic" factor. In tissue cultures norepinephrine stimu- 
lates the growth and hypertrophy of cardiac cells [76]. 
Furthermore, sympathetic stimulation of kidneys in- 
creases the release of renin, leading to high plasma 
angiotensin values, and in mild hypertension high 
renin is characteristically found in patients with ele- 
vated plasma norepinephrine values [23]. Angiotensin 
is also a known trophic factor [77]. Thus both angio- 
tensin and norepinephrine, when elevated, will fur- 
ther aggravate the pressure-induced tendency for car- 
diac hypertrophy. 
Coronary s p a s m s  
A final mechanism by which sympathetic overactivity 
may contribute to coronary pathology in hypertension 
is through its trophic effect on vascular smooth muscle 
hypertrophy. Hypertrophy of the smooth muscle in 
the medial layer of a vessel's wall causes the wall to 
encroach upon the lumen and this potentiates vasocon- 
striction. There is good evidence that coronary resis- 
tance vessels in hypertension are hyper-responsive to 
vasoconstriction stimuli [78]. It is also reasonable to 
assume that sympathetic stimulation may play a role 
in this hyper-reactivity. In a case of another vascular 
bed - -  the human forearm - - ,  our own data support 
the role of sympathetic overactivity in the genesis of 
vascular hypertrophy in mild hypertension. Residual 
vascular resistance during maximal vasodilatation, a 
measure of the thickness of the wall at the point when 
the smooth muscles are fully relaxed, is elevated in 
borderline hypertension, and in these subjects there 
was a positive correlation between minimal forearm 
resistance and plasma norepinephrine values [79]. 
Such an effect of sympathetics is most likely to be 
evidenced also in the coronary vasculature. 
Clinical Implication 
One of the major puzzles in clinical hypertension is 
the lesser efficacy of antihypertensive agents in re- 
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gards to coronary protection and prevention [80,81]. 
For example, both strokes and coronary heart disease 
show a linear relationship to increasing blood pressure 
levels, but blood pressure reduction is much more ef- 
fective in decreasing strokes than in reducing coro- 
nary events in hypertension. Whereas this finding 
seems to be paradoxical to some epidemiologists and 
they have difficulties in accepting it, to a student of 
the pathophysiology of hypertension this state of af- 
fairs is fully expected. The syndrome of hypertension 
is complex and, in addition to blood pressure eleva- 
tion, also includes a number of metabolic and hemody- 
namic abnormalities, which are, in their own right, 
conducive to coronary morbidity. Understanding the 
pathophysiology of these associated factors is the pre- 
condition for a more rational and potentially more ef- 
ficacious treatment of hypertension. Since autonomic 
abnormality plays a major role in the genesis of these 
associated risk factors, it stands to reason that cen- 
trally acting antihypertensive agents ought to be par- 
ticularly useful in that regard. Future research is 
needed to evaluate whether this theoretical expecta- 
tion can be translated into a demonstrable clinical ad- 
vantage. 
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